Online inquiry

IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5175MR)

This product GTTS-WQ5175MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL13 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001354991.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3596
UniProt ID P35225
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5175MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11200MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ14030MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA aLAG367
GTTS-WQ8707MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HuMax-TF-ADC
GTTS-WQ2333MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ALXN6000
GTTS-WQ9508MR IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA J2898A
GTTS-WQ6752MR IVTScrip™ mRNA-Anti-EGFR, DS 992(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DS 992
GTTS-WQ3980MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BG9924
GTTS-WQ11496MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MetMAb
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW